Upstream Bio, Inc. $UPB Shares Bought by UBS Group AG

UBS Group AG lifted its position in shares of Upstream Bio, Inc. (NASDAQ:UPB) by 563.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,806,243 shares of the company’s stock after buying an additional 1,533,972 shares during the period. UBS Group AG’s holdings in Upstream Bio were worth $49,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Integral Health Asset Management LLC purchased a new stake in Upstream Bio in the third quarter valued at $10,816,000. Rafferty Asset Management LLC acquired a new stake in shares of Upstream Bio during the 3rd quarter worth about $649,000. New York State Common Retirement Fund raised its holdings in Upstream Bio by 34.0% in the 3rd quarter. New York State Common Retirement Fund now owns 6,300 shares of the company’s stock valued at $119,000 after buying an additional 1,600 shares during the period. Creative Planning acquired a new position in Upstream Bio in the second quarter valued at about $154,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Upstream Bio during the second quarter worth about $145,000.

Upstream Bio Price Performance

Upstream Bio stock opened at $9.19 on Thursday. The stock’s fifty day moving average is $9.07 and its two-hundred day moving average is $19.82. The stock has a market cap of $500.12 million, a PE ratio of -3.44 and a beta of 1.28. Upstream Bio, Inc. has a 1-year low of $7.25 and a 1-year high of $33.68.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06). Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. The business had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. On average, research analysts expect that Upstream Bio, Inc. will post -3.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on UPB. Wall Street Zen lowered Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Finally, Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective for the company. in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.